Abstract: Platensimycin was recently discovered by Merck Research Laboratories and has created considerable interest given its potent antibacterial activity and mode of action. The use of RNA gene-silencing techniques and screening libraries of natural products allowed Merck to find this antibiotic which may have otherwise been missed using conventional methods. Interestingly, platensimycin has shown good activity against a panel of Gram positive organisms which included various resistant strains. Platensimycin works by inhibitingketoacyl synthases I/II (FabF/B) which are key enzymes in the production of fatty acids required for bacterial cell membranes. So far, a number of groups have explored synthetic strategies for platensimycin and this work has subsequently lead to the synthesis of active analogues. Given its mode of action, it is intriguing as to why Merck themselves patented only a single compound and have not apparently sought to generate further libraries. This review will discuss the origins of platensimycin, its mechanism of action, synthetic schemes and where the future may take us following this fascinating discovery.
INTRODUCTION
To some extent, research into finding novel antibiotics is no longer carried out by the large pharmaceutical companies. Taking any drug to market is tough with many hurdles to jump and numerous places to trip over. Poor pharmacokinetics, toxicity and drug resistance can all spell doom for a drug. If successful however, antibiotics often see limited use in the clinic in order to minimize resistance problems which then stifles their ability to recoup the costs of development. Clinically however, there is an urgent need for new compounds to challenge the multidrug-resistant organisms that are becoming problematic in our hospitals [1, 2] . In addition, incentive schemes have been proposed to encourage antimicrobial research such as revised FDA guidelines and tax breaks [2, 3] . So when the discovery of a new antibiotic (platensimycin, Fig. (1A) ) *Address correspondence to this author at the Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia; E-mail: David.Manallack@vcp.monash.edu.au based on a novel chemical scaffold was heralded [4] there was an air of excitement that another agent may become available for clinical use. Platensimycin has since spawned a series of papers detailing the methods behind the discovery together with synthetic strategies oriented to platensimycin itself as well as close analogues. Certainly the interest of many scientists has been stimulated and this is a research area that will undoubtedly grow. The distinct possibility remains that either platensimycin will emerge as a drug or another agent will be developed that exploits the same mechanism of action. This review will highlight the key publications regarding platensimycin focusing on the discovery, mechanism of action and chemistry of this interesting compound.
THE DISCOVERY OF PLATENSIMYCIN
In recent decades considerable effort has been put into developing new assays to improve the identification of antibiotic substances. Typically, either empiric whole cell screening is used or in vitro assays against specific targets are employed to examine anti- bacterial activity. A problem encountered with the latter method is that while potent compounds are found they are often inactive in whole cell screens due to poor cell penetration [5] or are actively removed by the bacteria [6] . Whole cell screening also has limitations as it is not able to distinguish between general toxicity and specific antibacterial activity. To improve screening methods an assay that could employ whole cell systems as well as being targetbased was sought. One way to do this is to genetically manipulate specific biological targets (e.g. mutant strains may be compared against wild type bacteria) however these are often time-consuming to generate and are not applicable in all cases. A target selective method that could be applied more generally without the complexities of specific mutations was required. This is even more compelling given that there are an estimated 150 to 670 essential proteins conserved between pathogenic bacteria that represent potential drug targets [7] [8] [9] [10] [11] .
To address these needs two groups explored antisense RNA methods which have now been developed and implemented for use in the discovery of new antibiotics [8, 11] . The method operates by sensitizing a particular target protein by the expression of antisense RNA against the target itself. By expressing the antisense RNA this ultimately results in a reduction in the levels of the target protein.
Comparisons can then be made against the strain with the depleted protein and normal strains, particularly with drugs that target the protein of interest. To achieve this both groups cloned and introduced random DNA fragments seeking growth inhibition when these were induced by a either a tetracycline [8] or xylose-regulated vector [11] . To showcase the method, FabF ( -ketoacyl synthase II) and related targets were investigated employing a two plate system [12] where control organisms were compared to cells expressing fabF antisense RNA. Compounds were spotted onto agar plates and only those that inhibited FabF generated differing zones of inhibition. The technique therefore, is capable of differentiating between antibiotic classes with particular regard to the target of interest thus providing vital clues to the mechanism of action. Further drug targets are likely to be explored and indeed this method should lead to the development of significant collections of bacteria with various inducible RNA antisense sequences suitable for large scale drug discovery.
Merck themselves screened over 250,000 microbial extracts using the two-plate system described above [13] . The advantage of the method is that the concentrations of compounds in these extracts is sometimes too low to be identified in whole cell assays but are easily found in this two-plate assay system. From more recently acquired natural product sources, platensimycin was identified in an extract of Streptomyces platensis found in soil samples from South Africa and Spain [4] . Various procedures were used to obtain a sample of platensimycin and to elucidate its structure. This involved reverse-phase HPLC, mass spectrometry (HRESIFT-MS) and 2D-NMR experiments. While this was a challenging task, Xray crystallographic analysis of the 6'-bromo derivative of platensimycin provided the absolute stereochemistry of the molecule [4] . During this work platensimycin was patented [14] but surprisingly this was limited to platensimycin itself and did not include any description of analogues or congeners. Release of this information has meant that research into platensimycin has been quick to take off with papers emerging on the synthesis of platensimycin, [4, [15] [16] [17] [18] [19] [20] the identification of the related compound platencin [21, 22] and the first emergence of platensimycin analogues [4, 13, 23] .
FATTY ACID SYNTHESIS II
Fatty acid synthesis (FAS) is a key requirement for most organisms and two major types of protein synthesis architecture are known to exist. FAS I is found in eukaryotic organisms such as mammals and fungi with synthesis being carried out by a large multifunctional protein [24] [25] [26] . FAS II occurs in prokaryotes (bacteria, plants and parasites) where each step in the synthetic pathway is encoded by separate proteins [27, 28] . This pathway includes enzymes that are involved in condensation, reduction and dehydration of the fatty acid substrate. The condensing enzymes play a key role by elongating the fatty acid chain by two carbon units [29] [30] [31] and of particular interest are the enzymes FabF/B which have come under scrutiny as potential targets for antibiotic research [27, 32, 33] . As yet no inhibitors of these enzymes have emerged as clinical agents however compounds such as thiolactomycin [34] and cerulenin [35] (Figs. (1B, 1C) ) have been identified as weak inhibitors. Other compounds known to inhibit FabI within the FAS II pathway include triclosan [36] (commonly used in toothpaste and soap) and isoniazid [37] (tuberculosis treatment). Certainly, FAS II is a fertile area of research and is actively being pursued to find new antibiotic agents.
The mechanism of the condensation reaction of FabF/B has been clarified considerably through the use of crystal structures and site directed mutagenesis of key amino acid residues [38] . Fig. (2) shows a simplified scheme for the overall process which is essentially a Claisen condensation [39] operating through a series of sequential steps as listed here [25, 28, 38, [40] [41] [42] ]:
1.
Acyl carrier protein (ACP) transfers the growing fatty acid to the enzyme (FabF/B) and binds to the active site thiol of Cys163 [N.B. the numbering scheme of ecFabF [13] (2GFX) will be used throughout]. Formation of the acylenzyme intermediate allows ACP to be released.
2.
A conformational change in the enzyme then occurs where the side chain of Phe400 moves aside to reveal the malonyl binding site which is known as the 'open configuration' of the enzyme. Malonyl-ACP is now able to bind to the enzyme and undergoes decarboxylation to generate a carbanion species which itself reacts with the acyl-enzyme intermediate. 3. Finally, the reaction cycle finishes with the release ofketoacyl-ACP, bicarbonate and the free enzyme.
Aspects of the mechanism are also worth noting here given that many of the amino acids interact with platensimycin and are influential when considering docking studies. Firstly, the thiol group of Cys163 is activated through the dipole moment of helix N 3 which lowers the pK a [43] of this functional group. The nucleophilicity of the cysteine is facilitated by an oxyanion hole formed with the backbone amides of Cys163 and Phe400. Interestingly, the crystal structure complex with platensimycin employed a C163Q mutant which gave a 50-fold increase in apparent binding [13] . The Gln163 residue lies adjacent to the carboxylate of platensimycin but makes no specific hydrogen bond. Given the close proximity of the carboxylate of platensimycin (presumed to be an anion) to the anionic thiol of Cys163 in the wild type enzyme may suggest the reason behind the increase in binding of the C163Q mutant. The second set of residues worth considering comprises His303 and His340 which play a role in the decarboxylation mechanism of the malonyl moiety. In particular, His303 activates a structured water to attack the carboxylate of the incoming malonyl-ACP [38] . The crystal structure of FabF also demonstrates that His340 forms a hydrogen bond between the amide nitrogen of Leu342 and the N atom of the imidazole ring meaning that the lone pair must reside on this atom [13, 38] . In the platensimycin crystal structure the structured water adjacent to His303 is no longer present which may suggest an alternative electronic state for this residue. A strong possibility exists that His303 would present itself as a cation capable of forming an ionic interaction with the benzoic acid group of platensimycin [13] .
CRYSTAL STRUCTURE OF PLATENSIMYCIN BOUND TO ecFabF(C163Q)
Platensimycin interacts with the malonyl binding site of FabF after the enzyme has formed the acyl-enzyme intermediate [13] (i.e. open configuration). The ecFabF(C163Q) mutant is extremely useful as it mimics the open configuration where Phe400 adopts a conformation usually observed in the acyl-enzyme intermediate [13] . This mutation also has the effect of affording greater affinity of platensimycin for the enzyme. The structure of platensimycin (Fig.  (1A) ) can be considered to be made up of two halves. The aromatic portion contains a substituted benzoic acid while the right hand side contains a complex polycyclic ketolide joined by a flexible propionamide chain. When bound to the enzyme the benzoic acid moiety buries deep into the protein and interacts with the amino acids that make up the catalytic triad (Cys163, His303, His340). Fig. (3) shows the key interactions with the binding site and this location also coincides with the position of thiolactomycin when bound to the enzyme [44] . An edge to face interaction is made with the Phe400 residue and the benzoic acid ring. The carboxylic acid group interacts with His303 and His340 which may mimic the location of the acid in malonyl-ACP. The hydroxyl group para to the carboxylate forms an interaction with a water molecule which in turn binds to the side chain of Asp265. Specific interactions are not made with the other hydroxy group but it may have a conformational role in keeping the amide perpendicular to the aromatic ring. In this configuration the amide forms two hydrogen bonds where the carbonyl oxygen binds to the side chain of Thr307 and the nitrogen to the backbone carbonyl of Thr270. Fig. (3) shows some of the interactions with the ketolide highlighting the carbonyl hydrogen bond with the backbone amide nitrogen of Ala309 and the ether oxygen interaction with the sidechain of Thr270. Interestingly, Wang et al. suggested that resistance would be unlikely to occur with platensimycin given the nature of the interactions it makes with backbone atoms and amino acids vital to the function of the enzyme [13] . While this is an encouraging assessment caution should be exercised and resistance development studies may need to be explored. As a cautionary note, it was also hoped that linezolid would remain free of these problems but resistant strains emerged shortly after the drug was launched [45] .
Docking Studies
A limited series of docking experiments were conducted using the ecFabF C163Q protein structure (2GFX) [13, 46] . The protein was used both in the C163Q form and where the glutamine was modified back to the cysteine. In this latter case Cys163 was modelled as the thiolate anion in accord with the pK a of this residue [43] . Residues His303, Lys335 and Glu349 were modelled as the charged species after carefully examining the protein structure. This decision was reinforced following an examination of the mechanism of action of the enzyme as well as assimilating the comments of previous researchers [13, 38] . Furthermore, key water molecules were retained in the active site ensuring appropriate hydrogen bond orientation. The Glide software package (http://www.schrodinger. com) was used to dock platensimycin, platencin and adamantaplatensimycin (Fig. (1) ) into both proteins and their fit was assessed using both docking scores and visual inspections. Table 1 shows that platensimycin docked with the best fit score followed by platencin and adamantaplatensimycin. The fit of platensimycin back into ecFabF C163Q was remarkably similar to the orientation of the compound in the crystal structure (RMS 0.26 Å) demonstrating the same hydrogen bond network. Platencin and adamantaplatensimycin fitted into the protein in a very similar manner to platensimycin. In particular, the aromatic part of these molecules bound in the same configuration as platensimycin and the carbonyl group on the multi-ring system mimicking the ketolide making the same hydrogen bond interaction with Ala309. Given the lack of an ether oxygen in the ring systems of platencin and adamantaplatensimycin they were unable to form a hydrogen bond with Thr270. This loss of an interaction may explain the lower fit scores for these compounds but must be considered alongside other factors such as reduced shape complementarity. The rank order of potency as suggested by the scores does not quite tally with the potency of these compounds where platencin was found to be less potent than adamantaplatensimycin [13, 21, 23] . Nevertheless, the impressive docking results for platensimycin mean that in silico screening of synthetic candidates is feasible and a logical next step is to explore additional enzymes in the FAS II pathway. 
BIOLOGICAL ACTIVITY OF PLATENSIMYCIN
Platensimycin has been extensively studied both in vitro and in vivo to establish its spectrum of activity and characteristics. Standard microbiology experiments showed that platensimycin inhibited This compared well to linezolid which demonstrated MIC's from 1 to 4 g/ml against the same set of organisms. In wild type E. coli platensimycin was ineffective but showed moderate potency against strains where an efflux mechanism had been disabled (E. Coli(tolC)) [13] . Various enzyme inhibition and binding experiments were also undertaken showing reasonable potency for platensimycin against FabF. Confirmation of the mechanism of action was demonstrated using whole cell labelling to examine DNA, RNA protein, cell wall and lipid biosynthesis. Of these processes only lipid biosynthesis was affected thus confirming the mode of action of this compound [13] .
Mice infected with S. aureus were treated with platensimycin at different concentrations through continuous-delivery pumps into the jugular vein. Impressive reductions in viable cell numbers from infected kidneys were seen with doses of 150 g/h (over 24 hours) resulting in 40% of kidneys showing no viable S. aureus. More importantly toxicity was not observed in these animals and this was also the case for a further group treated with platensimycin over a total of 17 days at varying doses [13] . A lack of toxicity in HeLa cells challenged with platensimycin is also encouraging. Overall the profile of platensimycin appears promising. It has been suggested that the need for continuous infusion together with low plasma concentrations (e.g. at 100 g/h gave plasma exposure of 0.6 g/ml which is below the MIC of 2 g/ml for S. aureus in plasma) indicates poor pharmacokinetics [47, 48] . Singh and coworkers have since acknowledged [19] this deficit and it would seem likely that platensimycin has stability problems or unsuitable pharmacokinetics worthy of further investigation.
PLATENCIN
The same Merck team that identified platensimycin [13] recently described their finding of platencin [21, 22] (Fig. (1D) ), an antibiotic with a similar structure and profile to platensimycin. While coming from a related strain of Streptomyces platensis (MA7339) this particular organism did not additionally produce platensimycin. Platencin differs from platensimycin both in the ketolide portion of the molecule (Fig. (1) ) and its biological profile. MIC values against a panel of organisms were similar between the compounds except platencin showed lower activity in the presence of serum and an improved activity against E. Coli(tolC). Once again low toxicity was observed and in vivo models demonstrated reasonable activity. The most important difference was the enzyme inhibition profile of platencin which demonstrated a dual activity against FabF and FabH. Potency against FabF (IC 50 = 0.113 M) was about 6 fold less than platensimycin while inhibition of FabH (IC 50 = 16.2 M) was 4 fold more potent. By themselves these IC 50 values are unremarkable but in combination they have a synergistic effect on inhibiting bacterial cell growth [21, 22] . Jayasuriya and co-workers [21] also conducted docking experiments to explain these potency differences and it is tempting to envisage the design of an analogue that maximizes inhibition at both these enzymes to exploit the synergistic effect on antibacterial activity.
SYNTHESIS OF PLATENSIMYCIN AND ANALOGUES
Synthetic chemistry efforts regarding platensimycin broadly fall into two areas. Strategies oriented to the synthesis of platensimycin and those that have employed platensimycin as a starting point to make analogues. A third and burgeoning area of research has commenced aimed at making platensimycin analogues de novo [23] . Nicolaou and his team were the first to describe the total synthesis of platensimycin (Fig. (4) ) [15] . Their strategy involved the synthesis of the aromatic portion of platensimycin (i.e. 3-amino-2,4-dihydroxybenzoic acid) in a protected form starting from 2-nitroresorcinol in five steps. The pentacyclic ketolide was generated in a fifteen step synthesis starting from 3-ethoxycyclohex-2-en-1-one. Coupling of each half of the molecule was readily achieved and subsequent deprotection furnished racemic (±)-platensimycin. Synthesis of the active enantiomer of platensimycin has since been addressed by this group [18] . Nicolaou astutely noted in their paper [15] that they expected a variety of syntheses to be reported following their publication and this indeed has been the case.
Other groups involved in the synthesis of the pentacyclic ketolide include Li and co-workers [20] where they employed a Robinson annulation approach starting from methyl acrylate and methyl- Fig. (4) . Overall synthetic scheme for the assembly of platensimycin.
cyclopentadiene. An alternative scheme was described by Zou et al. [17] who generated the ketolide starting with 5-methoxy-1-tetralone, however this gave a racemic product. Kaliappan and Ravikumar [16] also described a model study that generated a related intermediate of this complex ring system. Synthesis of analogues using platensimycin as the starting point was initiated by the original discovery group who produced 6-bromoplatensimcyin [4] , dihydroplatensimycin [4, 13] and [ 3 H]dihydroplatensimycin for use in binding studies [13] . Further chemistry was outlined in a more recent paper which described the application of a range of reactions such as methylation, halogenation, reduction, epoxidation and Bayer-Villiger oxidation on platensimycin [19] . This work did not appear to have any specific design associated with it and merely sought to explore a variety of chemical reactions relevant to the functional groups on the parent molecule. In each case the activity of the compounds produced was less than platensimycin. Additional studies were also dedicated to understanding the conversion of dihydroplatensimycin to a series of cyclic forms first encountered during earlier research [4] .
As mentioned earlier, the generation of analogues synthesized de novo has begun with the emergence of adamantaplatensimycin [23] . This compound was made using bromoadamantane as the starting point for the ketolide portion of the molecule. Fig. (1E) shows the structure of adamantaplatensimycin illustrating the lack of an ether oxygen within the ring system that mimics the ketolide group of platensimycin. Despite this, the molecule showed impressive antibiotic potential demonstrating activity slightly less than platensimycin against two Gram positive organisms. This molecule is certainly destined for further study and it is easily anticipated that more analogues will emerge. A quick assessment of the physicochemical properties of platensimycin and related compounds showed that in general terms they do not violate Lipinski's guidelines [49] (Table 2) . Of concern is the high value of the polar surface area (PSA) which exceeds 120Å 2 [50] . Certainly the polar nature of the aromatic ring contributes significantly to the PSA and this result perhaps hints at reasons for the observed poor pharmacokinetics of platensimycin. Future design work will need to consider this aspect of the physicochemical properties of these compounds.
CONCLUSIONS AND FUTURE DIRECTIONS
Of critical importance to maintaining the potency of our antibiotic arsenal is the interplay between pharmacists, doctors and their patients. Guidelines for prescribing and administering antibiotics are vital to hold back the tide of resistant bacteria. Alongside this, of course, is the continual need for new antibiotics and research into novel ways of curtailing resistance [51] . The studies outlined in this review targeting FAS II certainly suggest that this is a fertile area with enormous potential to generate a new generation of clinically useful antibiotics. While Merck patented platensimycin in isolation [14] it is unknown if this specific line of research will be followed up. It is easy to speculate that platensimycin was primarily a showcase study for the RNA gene-silencing techniques and that more valuable/approachable antibiotic targets are being explored with a view to generating compounds with a greater probability of success.
Given that mammalian FAS has a key step involving condensation with a malonyl-ACP moiety, it would be interesting to compare the FabF active site with its mammalian counterpart. At present the mammalian crystal structure has somewhat poor resolution (4.3 Å) [26] and it may be that this needs to await either further resolution or crystallization with inhibitors or substrate mimics to clarify the nature of the malonyl binding site. One potential area for the toxicity of platensimycin may be an interference with mammalian FAS. Encouragingly, the limited mouse studies conducted so far suggest platensimycin is not toxic [13] and the FabI inhibitor triclosan is also considered to be a safe compound. Of course, further toxicity studies are warranted when compounds get closer to being selected as clinical candidates, however molecular modelling may, in time, be able to predict whether platensimycin is capable of binding to human FAS.
One of the most interesting findings from the work revealed so far was that platencin showed activity against both FabH and FabF. This dual inhibition exhibited a synergistic effect on bacterial cell growth. Indeed, this may also provide a way of delaying resistance if bacteria need to address challenges to two enzymes in a vital synthetic pathway. Given that the crystal structures of FabH and FabF are available it would be sensible to design compounds that are capable of interacting at both enzymes to exploit the synergies described for platencin. Our own work and that of Jayasuriya [21] have shown that modelling can begin to understand and quantify the molecular interactions between these antibiotics and their respective targets. As each author in this field has reiterated in their papers, this is an area where we expect to see a lot more research and this review has perhaps only viewed the tip of a very large iceberg. 
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